The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Company Gifts Linked to Doctors’ Prescribing Habits

Drug Company Gifts Linked to Doctors’ Prescribing Habits

May 15, 2016 • By Andrew M. Seaman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Doctors who receive payments or gifts from pharmaceutical companies are more likely to prescribe brand name medications, a new study suggests.

You Might Also Like
  • Inefficient Prescribing Costs Billions of Healthcare Dollars
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System

Dr. James Yeh, of Brigham and Women’s Hospital in Boston, and colleagues write May 9 online in JAMA Internal Medicine that some states require doctors to report what they receive from drug companies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the new study, the researchers analyzed 2011 data from Massachusetts payment reports and the prescription drug program of Medicare, the U.S. public health insurance program for the elderly and disabled.

Of the 2,444 Massachusetts doctors in Medicare’s prescribing database, about 37% received payments from the drug industry.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

About 71% of doctors reported receiving meals paid for by drug companies, about 51% reported receiving grants, about 27% received other services and about 11% reported receiving educational training.

Average payments to doctors ranged from $100 to $1,188, the researchers report.

Then the researchers looked at whether those payments were tied to doctors’ prescribing patterns. Specifically, they wanted to know whether doctors who received more gifts prescribed more brand-name cholesterol lowering drugs—known as statins—rather than less expensive generic medications.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, an average of 17.8% of statin prescriptions were for brand name drugs. Every $1,000 of additional funds doctors received was tied to a 0.1% increase in the rate of brand name prescribing.

Although a 0.1% increase may not seem like a lot, the researchers note that the financial effects for patients and the healthcare system can be substantial because brand name statins cost between two and four times more than generic medications.

There was no connection between brand name prescribing and industry payments when doctors received less than $2,000.

“Not surprisingly, the payments that were categorized as educational trainings seemed to most impact brand name prescribing,” says Yeh.

The researchers say their findings are limited by the fact that doctors who prescribe a high number of brand name medications may be sought out by drug companies to promote those products. Also, the findings are based on self-reporting by doctors.

Filed Under: Drug Updates, Pharma Co. News, Professional Topics Tagged With: generic drugs, physician, prescribe, Prescription drugs, Statin

You Might Also Like:
  • Inefficient Prescribing Costs Billions of Healthcare Dollars
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • U.S. Tribal Patent Deal Could Impact Generic Drug Market

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)